]>
IRCT201502122804N8 IRCT 2015-06-04 Vice chancellor for research, Shahid Rajaei Heart Center Intermittent furosemide therapy as a prophylaxis of acute renal failure in CABG patients Intermittent furosemide therapy as a prophylaxis of acute renal failure in CABG patients: is it effective? A clinical trial 2008-12-31 anticipated 123 Complete https://irct.ir/trial/2650 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Other design features: a tertiary level, referral university hospital. 3 Coronary artery disease. Intervention 1: 2. group B: intermittent furosemide therapy; these patients received 0.2 mg/kg furosemide during CABG only in the case of decreased urinary excretion rate below the determined level in the study. Intervention 2: 1. group A: intra-prime furosemide therapy; these patients received 0.3-0.4 mg/kg furosemide in the prime solution. Intervention 3: 3. group C: the control group.
public Ali Dabbagh
Anesthesiology Research Center, Velenjak, Shahid Beheshti University of Medical Sciences
Tehran Iran (Islamic Republic of) 1985717443 +98 21 2243 2572 alidabbagh@yahoo.com: alidabbagh@sbmu.ac.ir Anesthesiology Research Center scientific Ali Dabbagh
Anesthesiology Research Center, Velenjak, Chamran Exp Way, Tehran, Iran
Tehran Iran (Islamic Republic of) 1985717443 +98 21 2243 2572 alidabbagh@yahoo.com; alidabbagh@sbmu.ac.ir Anesthesiology Research Center Iran (Islamic Republic of) Inclusion criteria: age 40-75; elective CABG with CPB; constant surgeon; informed written consent; Exclusion criteria: old age above 75 years; emergency surgery; high risk surgery; ischemic heart disease; diabetes mellitus; diabetic ketoacidosis; non-ketonic hyperosmolar diabetic coma; acute renal failure; chronic kidney disease causing serum Cr>2mg/dL; glomerulonephritis; hepatic failure causing liver function test failure (> 3 times than normal); off pump CABG; any unwanted complication in the operation period; re-starting CPB after weaning from bypass; pulmonary artery pressure >30 before operation; ejection fraction<30%; re-operation in the postoperative period; congestive heart failure; thyroid disorders; acute infections; stroke; pregnancy; hospital admission in the recent 3 months; 18 years 75 years Both I25.1 Atherosclerotic heart disease Treatment - Drugs Treatment - Drugs Placebo 2. group B: intermittent furosemide therapy; these patients received 0.2 mg/kg furosemide during CABG only in the case of decreased urinary excretion rate below the determined level in the study 1. group A: intra-prime furosemide therapy; these patients received 0.3-0.4 mg/kg furosemide in the prime solution 3. group C: the control group Postoperative serum markers of renal function including Glomerular Filtration Rate (GFR). Timepoint: Preoperative levels and also early postoperative period (mainly 24 hours). Method of measurement: level of serum markers; then using the Cockcroft-Gault formula. Acid-base and electrolytes of the plasma. Timepoint: before the intervention and 24 hours after intervention. Method of measurement: serum levels of markers. Vice chancellor for research, Shahid Rajaei Heart Center Approved 2010-04-20 Rajaei Heart Center Research Ethics Comittee Research Deputy, Rajaei Heart Center, Vali Asr Ave Tehran Iran (Islamic Republic of)